Liraglutide - 4Moving Biotech
Alternative Names: 4P 004Latest Information Update: 15 Jun 2024
At a glance
- Originator INSERM; Sorbonne University
- Developer 4Moving Biotech; 4P-Pharma
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Osteoarthritis
Most Recent Events
- 10 Jun 2024 4Moving Biotech announces intention to to secure accelerated approvals in USA and EU for Osteoarthritis
- 10 Jun 2024 4Moving Biotech receives constructive pre-IND guidance from the US FDA in advancing its clinical development strategy
- 10 Jun 2024 Adverse events and pharmacokinetics data from a phase I trial in Osteoarthritis released by 4Moving Biotech